Nyxoah is a neurotechnology company developing implantable neuromodulation therapies for the treatment of obstructive sleep apnea. The company focuses on addressing airway collapse during sleep by targeting neural control of upper airway muscles rather than relying on mechanical ventilation.

Its core system delivers electrical stimulation to the hypoglossal nerve to maintain airway patency during sleep. The device is fully implantable and controlled externally, enabling therapy personalization while minimizing patient burden and adherence challenges associated with CPAP.

Nyxoah’s technology is deployed in clinical sleep medicine settings as a regulated medical device. The company positions its platform as a clinically validated neuromodulation therapy offering an alternative treatment pathway for patients with moderate to severe obstructive sleep apnea.